

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q85522

Shinji NAKADE, et al.

Appln. No.: 10/519,113

Group Art Unit: 1628

Confirmation No.: 9389

Examiner: RICCI, CRAIG D

Filed: November 1, 2005

For: PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASE DUE TO  
VASCULAR CONSTRICTION OR VASODILATION

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98**

**MAIL STOP AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of the listed document is submitted herewith. Applicant submits a European Office Action dated July 14, 2010, which was issued in a corresponding European Application No. 03761797.4. It is noted that two references (WO 01/69252, WO 01/98301) were previously submitted in an Information Disclosure Statement on December 23, 2004 and one reference (WO 02/42301) was previously submitted in an Information Disclosure Statement on September 18, 2009.

The present Information Disclosure Statement is being filed after either a Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution in the application

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98  
U.S. Appln. No.: 10/519,113

Attorney Docket No.: Q85522

(whichever is earlier), but before payment of the Issue Fee, and therefore the fee of \$180.00 under 37 C.F.R. § 1.17(p) is being remitted, and a Statement Under 37 C.F.R. § 1.97(e).

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



---

Martin D. Ostrowski  
Registration No. 66,828

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

**65565**

CUSTOMER NUMBER

Date: September 23, 2010